Alnylam Soars 15.43% on $1.31B Trade Volume Surge as TTR Revenues Jump 64% and Raised 2025 Outlook

Alnylam Pharmaceuticals (ALNY) surged 15.43% on July 31, 2025, with a trading volume of $1.31 billion, up 86.18% from the prior day. The rally followed the company’s Q2 2025 results, which showed total net product revenues of $672 million, a 64% year-over-year increase, driven by $544 million in TTR franchise sales—a 77% rise. AMVUTTRA (vutrisiran) for ATTR-CM reached 1,400 patients by June 30 and secured approvals in the EU, Brazil, UK, and Japan. The TRITON-CM Phase 3 trial for nucresiran in ATTR-CM was initiated, and 2025 guidance was raised to $2.175 billion–$2.275 billion for TTR revenues and $2.65 billion–$2.8 billion for total product sales.

The TTR growth was fueled by AMVUTTRA’s adoption in ATTR-CM, with CEO Yvonne Greenstreet highlighting the therapy’s market traction and patient access efforts. Collaborative revenue declines offset this growth, primarily due to a 2024 Regeneron partnership modification. Despite a GAAP operating loss of $16.2 million, non-GAAP income from operations fell 31% to $95.5 million. Alnylam’s cash reserves stood at $2.86 billion, supporting its pipeline advancements and upcoming trials, including zilebesiran’s cardiovascular outcomes study and mivelsiran’s Alzheimer’s trial.

Strategically, Alnylam’s raised guidance reflects confidence in AMVUTTRA’s expansion and the TRITON-CM trial’s potential. The company aims to solidify its position in rare diseases and cardiovascular innovation while navigating R&D costs and SG&A increases. With a robust cash position and a deep pipeline, Alnylam’s focus on sustainable profitability aligns with its P5x25 goals, positioning it to capitalize on high unmet medical needs in amyloidosis and other conditions.

The strategy of purchasing the top 500 stocks by daily trading volume and holding them for one day delivered a 166.71% return from 2022 to the present. This outperformed the benchmark return of 29.18%, generating an excess return of 137.53%. The strategy's success is attributed to its ability to capture momentum driven by high liquidity, as evidenced by the significant volume surges seen in stocks like VICI Properties and Eli Lilly. This strategy reflects a market trend where liquidity concentration is a key factor in driving stock prices, particularly over short-term horizons. The consistent high returns underscore the effectiveness of this approach within the current market environment, where rapid liquidity shifts can create substantial trading opportunities. However, it is important to note that this strategy relies heavily on market structure and dynamics, which can evolve over time, potentially impacting its future performance.